Advances in Carbohydrate Chemistry and Biochemistry by Derek Horton (Eds.) - Cartys Poetry Books
Acid-zeolite catalyzed formation of alkyl glucosides by Fischer glucosylation and by transacetalation of butyl glucosides. ...http://www.cartyspoetryjournal.com/index.php/library/advances-in-carbohydrate-chemistry-and-biochemistry-1-st-edition
Pterostilbene 4′-β-Glucoside Protects against DSS-Induced Colitis via Induction of Tristetraprolin
... Yingqing Chen,1 Jeongmin ... In the present study, we provide evidence that pterostilbene 4′-β-glucoside (4-PG) exerts its anti-inflammatory effects on DSS- ... Here, we showed that pterostilbene 4′-β-glucoside is more potent than pterostilbene in mediating the anti-inflammatory effect ... Here, we utilized pterostilbene 4′-β-glucoside (4-PG), a compound derived from pterostilbene, to investigate whether it has ...https://www.hindawi.com/journals/omcl/2017/9427583/
Household Products Database - Health and Safety Information on Household Products
Decyl Glucoside. 054549-25-6. 3.0-10.0. Glycerides, C16-18 and C18-unsatd. mono- and di-. 068424-61-3. ...https://householdproducts.nlm.nih.gov/cgi-bin/household/brands?tbl=brands&id=19039064
Rose Hand Cream Intense | Free People UK
Shop our Rose Hand Cream Intense at FreePeople.com. Share style pics with FP Me, and read & post reviews. Free shipping worldwide - see site for details.https://www.freepeople.com/uk/shop/rose-hand-cream-intense/
Natural Personal Care Products | Tom's of Maine
Decyl Glucoside Cleansing Agent. Corn and Coconut or Palm Kernel Oil. Dicaprylyl ether Skin Feel. Oils from Coconut (Coco ... Coco Glucoside Cleansing Agent. Corn and Coconut or Palm Kernel Oil. Cocos nucifera (coconut) oil Moisturizer. Coconut (Cocos ... Lauryl Glucoside Dispersant. Coconut or palm kernel oil and corn. Lavender and other natural oils Pleasant smell. Lavender ( ...http://www.tomsofmaine.com/products/ingredient-list
All Natural Shampoo | Free People UK
Decyl Glucoside. *Mentha Piperita (Peppermint) Oil. *Cocamidopropyl Betaine. *Argania Spinosa (Argan) Oil ...https://www.freepeople.com/uk/shop/all-natural-shampoo/
Powder Ascorbic Acid Factory, China Powder Ascorbic Acid Factory Manufacturers & Suppliers | Made-in-China.com
Ascorbic Acid 2-Glucoside (AA2G) CAS: 129499-78-1 with 99% Made by Manufacturer FOB Price: $90 - $100 / KG Min. Order: 100 KG ...http://www.made-in-china.com/products-search/hot-china-products/Powder_Ascorbic_Acid_Factory.html
diospyrodin (beta-1C-(1'S*,2'R*,3'R*,4'S*-1',2',3',4',5'-pentahydroxypentyl)-glucopyranoside) Summary Report | CureHunter
Glucosides: 155*diospyrodin (beta-1C-(1'S*,2'R*,3'R*,4'S*-1',2',3',4',5'-pentahydroxypentyl)-glucopyranoside) ...http://www.curehunter.com/public/keywordSummaryC511379-diospyrodin--beta-1C--1-S--2-R--3-R--4-S--1--2--3--4--5--pentahydroxypentyl--glucopyranoside-.do
Alkaloid glucosides are known, e.g. from Vicia, and Pentzold et al. (2014) discuss ways insects have of getting around such ... 2011) found that the pathways by which the glucosides linamarin and lotaustralin are synthesized in plant and insect use the ... A number of Fabaceae have cyanogenic glucosides. Here plant-insect interactions have been studied in detail, for instance, ... Trees or lianes to annual herbs; (coumarins/furanocoumarins), non-protein amino acids, esp in seeds (0), (cyanogenic glucosides ...http://www.mobot.org/MOBOT/research/APweb/orders/Fabalesweb.htm
Patent US7759044 - Low activation energy dissolution modification agents for photoresist ... - Google Patents
The DMAs are glucosides, cholates, citrates and adamantanedicarboxylates protected with acid-labile ethoxyethyl, ... The protected DMA glucosides (I), citrates (II), cholates (III) and adamantanedicarboxylates (IV) where the protecting group is ... The protected DMA glucosides (I), citrates (II), cholates (III) and adamantanedicarboxylates (IV) where the protecting group is ... Structure I is a glucoside, structure II is a citrate, structure III is a cholate and structure IV is an ...http://www.google.com/patents/US7759044?dq=6377161
Molecules | Free Full-Text | Antinociceptive and Antibacterial Properties of Anthocyanins and Flavonols from Fruits of Black...
... mice tests showed that cyanidin-3-O-glucoside (C3G), rutin (Ru) and isoquercetin (IQ) were the main active ingredients in the ... The C3G, cyanidin-3-O-rutinoside (C3R) and pelargonidin-3-O-glucoside (Pg3G) contents of MnTF were 8.2, 2.9 and 0.3 mg/g, ... O-glucoside (C3G), rutin (Ru) and isoquercetin (IQ) were the main active ingredients in the antinociceptive process. Stronger ...http://www.mdpi.com/1420-3049/23/1/4/htm
hydroquinone O-beta-D-glucopyranoside (CHEBI:18305)
hydroquinone O-β-D-glucopyranoside (CHEBI:18305) is a β-D-glucoside (CHEBI:22798) hydroquinone O-β-D-glucopyranoside (CHEBI: ...http://www.ebi.ac.uk/chebi/searchId.do?chebiId=18305
Patent US7750058 - Process for preparing closed-cell water-blown rigid polyurethane foams ... - Google Patents
... methyl glucoside, sucrose and sorbitol. Ethylene glycol is preferably used. ...http://www.google.com/patents/US7750058?dq=5708422
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory...
PRIMARY OBJECTIVES:. I. Estimate the maximum tolerated dose (MTD) of decitabine priming followed by sequential mitoxantrone hydrochloride/etoposide/cytarabine (MEC) chemotherapy in adults with relapsed/refractory acute myeloid leukemia (AML).. SECONDARY OBJECTIVES:. I. Determine, within the limits of a Phase 1/2 study, disease response and duration of remission.. II. Identify biomarkers (e.g., deoxyribonucleic acid [DNA] methylation and/or gene expression changes) associated with treatment responses.. OUTLINE: This is a phase I, dose-escalation study of decitabine followed by a phase II study.. Patients receive decitabine intravenously (IV) on days -9 to -5 (dose level 1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3).. INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving complete response (CR) or CR with incomplete platelet count recovery (CRp) may receive up to 2 courses of ...https://clinicaltrials.gov/ct2/show/NCT01729845?cond=%22Acute+myelomonocytic+leukemia%22&rank=18
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin...
PRIMARY OBJECTIVES:. I. Assess toxicities of combining vorinostat and bortezomib as maintenance therapy after autologous stem cell transplant (ASCT) for NHL.. SECONDARY OBJECTIVES:. I. Ability to complete planned therapy.. II. Time to disease progression, event-free survival.. III. Overall survival.. OUTLINE:. All patients receive carmustine intravenously (IV) over 3 hours on day -7; cytarabine IV twice daily (BID) over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of cluster of differentiation (CD)20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat orally (PO) once daily (QD) on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.. After completion of study treatment, patients are followed for at least 2 years. ...https://clinicaltrials.gov/ct2/show/NCT00992446?cond=%22mycosis+fungoides%22&rank=15
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin...
Participants on an antiretroviral regimen should be receiving treatment that is in accordance with the current International acquired immune deficiency syndrome (AIDS) Society guidelines; the specific agents are at the discretion of the investigator and use of agents currently available on an expanded access basis is allowed but use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) are prohibited; changes to highly active anti-retroviral therapy (HAART) therapy may be made if medically necessary (toxicity, failure of regimen, etc.); antiretroviral naïve participants: participants who are not on HAART at study entry MUST begin therapy (utilizing the above guidelines) AFTER one cycle of chemotherapy has been completed under protocol; changes to HAART therapy may be made if medically necessary (toxicity, failure of regimen, etc.); concurrent therapy with zidovudine or a zidovudine-containing regimen (including Combivir and Trizivir) will be ...https://clinicaltrials.gov/ct2/show/NCT01193842?recr=Open&cond=%22Lymphoma%22&rank=10
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic...
PRIMARY OBJECTIVES:. I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99).. II. To estimate the event free survival (EFS) of Arm brentuximab vedotin (BV) and Arm crizotinib (CZ) and contrast these to historical control data.. SECONDARY OBJECTIVES:. I. To determine the prognostic significance of minimal disseminated disease (MDD) at diagnosis and minimal residual disease (MRD) as measured by real-time (RT)-polymerase chain reaction (PCR) in peripheral blood.. OUTLINE: Patients are assigned or randomized into 1 of 2 treatment arms.. ARM BV:. COURSE A (COURSES 1, 3, AND 5): Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1, dexamethasone orally (PO) twice daily (BID) or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV ...https://clinicaltrials.gov/show/NCT01979536
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia - Full Text View -...
PRIMARY OBJECTIVES:. I. To determine the maximum tolerated dose (MTD) of bortezomib in combination with midostaurin and intensive chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML).. II. To define the specific toxicities and the dose limiting toxicity (DLT) of midostaurin and bortezomib in combination with intensive chemotherapy in relapsed/refractory AML.. SECONDARY OBJECTIVES:. I. To determine the rate of complete remission (CR) of midostaurin and bortezomib in combination with intensive chemotherapy. II. To determine the overall response rate (ORR). III. To characterize the biological activity of midostaurin and bortezomib to potentially increase endogenous phosphatase activity and therefore inhibit aberrant tyrosine kinases by assessing FLT3 and KIT tyrosine kinase activity as well as SHP-1(Anti-Src Homology Phosphatase-1)phosphatase activity. IV. To correlate the biological activity of midostaurin and bortezomib to potentially increase endogenous phosphatase ...https://clinicaltrials.gov/ct2/show/NCT01174888?cond=%22cytogenetically+normal+acute+myeloid+leukemia%22+OR+%22Leukemia%2C+Myeloid%2C+Acute%22&rank=2
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia -...
This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect ...https://clinicaltrials.gov/ct2/show/NCT00792948?term=stem+cell+transplant&recr=Open&fund=01&rank=2
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia - Full Text View -...
PRIMARY OBJECTIVES:. I. To determine the DLT, MTD, and the recommended Phase 2 dose of bortezomib in combination with MEC in patients with relapsed/refractory AML.. SECONDARY OBJECTIVES:. I. To describe the non-dose limiting toxicities associated with bortezomib in combination with MEC in patients with relapsed/refractory AML.. II. To describe any preliminary evidence of clinical activity of this combination (CR rate) in relapsed/refractory AML.. III. To determine the median CD74 antigen expression in patients achieving a response versus those patients not achieving a response.. OUTLINE:. This is a dose-escalation study of bortezomib.. Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11; and mitoxantrone IV, etoposide IV over 1 hour, and intermediate-dose cytarabine IV over 6 hours on days 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.. After completion of study treatment, patients are followed up at 4-5 weeks. ...https://clinicaltrials.gov/ct2/show/NCT01127009?cond=%22Acute+monoblastic+leukemia%22&rank=6
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory...
PRIMARY OBJECTIVES:. I. To evaluate engraftment of human leukocyte antibody (HLA) identical peripheral blood stem cell (PBSC) allografts given after conditioning with total-body irradiation (TBI) (200cGy) +/- fludarabine (fludarabine phosphate), 90 mg/m^2 and post-grafting immunosuppression with cyclosporine (CSP)/mycophenolate mofetil (MMF) in refractory or relapsed lymphoma patients following an initial autologous peripheral blood stem cell transplant (PBSCT) for disease cytoreduction.. II. To determine the non-relapse mortality at day 100 post-non-myeloablative allografting following mobilization and high-dose chemotherapy with autografting.. SECONDARY OBJECTIVES:. I. To determine the disease free survival and overall survival of non-myeloablative allografting following autologous PBSCT.. OUTLINE:. CONDITIONING REGIMEN: Patients with matched, related stem cell donors receive cyclophosphamide intravenously (IV) on days -6 and -5 and undergo TBI twice daily (BID) on days -3 to -1. Patients with ...https://clinicaltrials.gov/ct2/show/NCT00005803?recr=Open&intr=%22Stem+Cell+Transplantation%22&rank=3
Molecules | Free Full-Text | Fruit Pod Extracts as a Source of Nutraceuticals and Pharmaceuticals | HTML
Tripenoids: maslinic acid glucoside; linoleic acid, prosophylline, polyphenols. Antioxidant, antibacterial, antifungal, ... it results in the isolation of compounds such as 3-benzyl-2-hydroxy-urs-12-en-28-oic acid and maslinic acid-3-glucoside ( ... ginsenoside and cyanidin-3-glucoside. However, plant extracts can be toxic and contain excessive lethal constituents such as ...http://www.mdpi.com/1420-3049/17/10/11931/htm
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia - Full Text View - ClinicalTrials...
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia ...https://clinicaltrials.gov/show/NCT02101853
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients...
PRIMARY OBJECTIVES:. I. To determine the 2-year event-free-survival (EFS) for children with standard risk Down syndrome (DS) acute myeloid leukemia (AML) (minimal residual disease [MRD]-negative after one cycle of induction therapy) after elimination of high dose (HD) Ara-C (cytarabine) from the treatment regimen.. II. To determine the 2-year EFS for children with high risk DS AML (MRD-positive after one cycle of induction therapy) after intensification of treatment equivalent to that used for high risk AML in children without DS.. EXPLORATORY OBJECTIVES:. I. To determine the extent to which elimination of HD Ara-C from the treatment of standard risk DS AML decreases adverse events and resource utilization.. II. To determine if elimination of HD Ara-C from treatment of standard risk DS AML results in a significant decrease in the number of days per patient spent on protocol therapy compared to predecessor study AAML0431.. III. To determine if elimination of HD Ara-C from treatment of standard ...https://clinicaltrials.gov/ct2/show/study/NCT02521493?show_desc=Y
A-level Applied Science/Colour Chemistry/Dyes - Wikibooks, open books for an open world
The yellow dye in onion skins is made a of mixture of flavonoids: quercetin, kaempferol and quercetin-3-glucoside. ...https://en.wikibooks.org/wiki/A-level_Applied_Science/Colour_Chemistry/Dyes
Download our free solidary book to support research on VHL disease